Novel structurally designed vaccine for s. aureus α-hemolysin: Protection against bacteremia and pneumonia

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Adhikari, Rajan P ^a   Karauzum, Hatice ^a   Sarwar, Jawad ^a   Abaandou, Laura ^a   Mahmoudieh, Mahta ^a   Boroun, Atefeh R ^a   Vu, Hong ^a   Nguyen, Tam ^a   Devi, V Sathya ^a   Shulenin, Sergey ^a   Warfield, Kelly L ^a   Aman, M Javad ^a  

^a Integrated BioTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; ALUMINUM HYDROXIDE; GLUCOPYRANOSYL LIPID ADJUVANT STABLE EMULSION; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL TOXIN; HEMOLYSIN; IMMUNOGLOBULIN G; PRIMER DNA; RECOMBINANT VACCINE; STAPHYLOCOCCAL ALPHA-TOXIN; STAPHYLOCOCCUS ALPHA TOXIN;

ACTIVE IMMUNIZATION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; IMMUNOGENICITY; MOLECULAR MODEL; MOUSE; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PASSIVE TRANSPORT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEPSIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; WESTERN BLOTTING; ANIMAL; BACTEREMIA; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PLASMID; PNEUMONIA; RABBIT; SERODIAGNOSIS;

ANIMALS; BACTEREMIA; BACTERIAL TOXINS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYSIN PROTEINS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PLASMIDS; PNEUMONIA; RABBITS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; VACCINES, SYNTHETIC;

EID: 84862023918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038567     Document Type: Article

References (33)

1. Foster TJ, (2004) The Staphylococcus aureus "superbug". J Clin Invest 114: 1693-1696.
2. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F, (2006) Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 193: 1495-1503.
3. Bassetti M, Nicco E, Mikulska M, (2009) Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int J Antimicrob Agents 34 (Suppl 1): S15-19.
4. Bradley SF, (2005) Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 26: 643-649.
5. Chambers HF, (2005) Community-associated MRSA-resistance and virulence converge. N Engl J Med 352: 1485-1487.
6. Rooijakkers SH, van Kessel KP, van Strijp JA, (2005) Staphylococcal innate immune evasion. Trends Microbiol 13: 596-601.
7. Nizet V, (2007) Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 120: 13-22.
8. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, et al. (2010) Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202: 1050-1058.
9. Bubeck Wardenburg J, Schneewind O, (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294.
10. Brown DR, Pattee PA, (1980) Identification of a chromosomal determinant of alpha-toxin production in Staphylococcus aureus. Infect Immun 30: 36-42.
11. Aarestrup FM, Larsen HD, Eriksen NH, Elsberg CS, Jensen NE, (1999) Frequency of alpha- and beta-haemolysin in Staphylococcus aureus of bovine and human origin. A comparison between pheno- and genotype and variation in phenotypic expression. APMIS 107: 425-430.
12. Shukla SK, Karow ME, Brady JM, Stemper ME, Kislow J, et al. (2010) Virulence genes and genotypic associations in nasal carriage, community-associated methicillin-susceptible and methicillin-resistant USA400 Staphylococcus aureus isolates. J Clin Microbiol 48: 3582-3592.
13. Bhakdi S, Tranum-Jensen J, (1991) Alpha-toxin of Staphylococcus aureus. Microbiol Rev 55: 733-751.
14. Husmann M, Beckmann E, Boller K, Kloft N, Tenzer S, et al. (2009) Elimination of a bacterial pore-forming toxin by sequential endocytosis and exocytosis. FEBS Lett 583: 337-344.
15. Ragle BE, Bubeck Wardenburg J, (2009) Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77: 2712-2718.
16. Menzies BE, Kernodle DS, (1996) Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 64: 1839-1841.
17. Panchal RG, Bayley H, (1995) Interactions between residues in staphylococcal alpha-hemolysin revealed by reversion mutagenesis. J Biol Chem 270: 23072-23076.
18. Liang X, Yan M, Ji Y, (2009) The H35A mutated alpha-toxin interferes with cytotoxicity of staphylococcal alpha-toxin. Infect Immun 77: 977-983.
19. Fattom AI, Sarwar J, Ortiz A, Naso R, (1996) A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 64: 1659-1665.
20. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, et al. (1996) Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274: 1859-1866.
21. Wilke GA, Bubeck Wardenburg J, (2010) Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci U S A 107: 13473-13478.
22. Coffman JD, Zhu J, Roach JM, Bavari S, Ulrich RG, et al. (2002) Production and purification of a recombinant Staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli. Protein Expr Purif 24: 302-312.
23. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5: e13677.
24. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, et al. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
25. Parker D, Prince A, (2012) Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol 34: 281-297.
26. Bhakdi S, Muhly M, Fussle R, (1984) Correlation between toxin binding and hemolytic activity in membrane damage by staphylococcal alpha-toxin. Infect Immun 46: 318-323.
27. Caiazza NC, O'Toole GA, (2003) Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol 185: 3214-3217.
28. McElroy MC, Harty HR, Hosford GE, Boylan GM, Pittet JF, et al. (1999) Alpha-toxin damages the air-blood barrier of the lung in a rat model of Staphylococcus aureus-induced pneumonia. Infect Immun 67: 5541-5544.
29. Rose F, Dahlem G, Guthmann B, Grimminger F, Maus U, et al. (2002) Mediator generation and signaling events in alveolar epithelial cells attacked by S. aureus alpha-toxin. Am J Physiol Lung Cell Mol Physiol 282: L207-214.
30. Bhakdi S, Muhly M, Korom S, Hugo F, (1989) Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes. Infect Immun 57: 3512-3519.
31. Nara PL, Garrity R, (1998) Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 16: 1780-1787.
32. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, et al. (2008) Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26: 6189-6199.
33. Lin G, Nara PL, (2007) Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res 5: 514-541.